文献速递心境障碍会诊联络精神医学

干扰素与抗TNF治疗对杏仁核反应性的不同调节及其预测抑郁症状双向变化

Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms.
PubMed 文献 · Mol Psychiatry · 2020-05-26

该前瞻性研究纳入30例接受IFN-α治疗的丙肝患者和30例接受抗TNF治疗的炎性关节炎患者,在首次注射前后进行fMRI情绪面孔任务和血样采集,并随访3个月。IFN-α在4周时显著增加抑郁症状,抗TNF在24小时和12周显著改善抑郁症状;两者分别增强和减弱右侧杏仁核反应性,且这些变化可预测抑郁症状的变化。

要点

  • IFN-α在4周时显著增加HAM-D抑郁评分,但首次剂量后4小时未增加。
  • 抗TNF在24小时和12周均显著改善HADS抑郁症状。
  • 右侧杏仁核反应性变化可预测IFN-α所致4周抑郁加重和抗TNF所致24小时抑郁改善。

核心结论

  • IFN-α和抗TNF通过调节杏仁核情绪反应性分别增强和减弱抑郁症状,提示系统性炎症对杏仁核反应性的作用在炎症相关抑郁症状中具有机制性意义。

研究设计与样本

  • 前瞻性研究,招募30例接受IFN-α治疗的丙肝患者(平均48.0±10.5岁,21例男性)和30例接受抗TNF治疗的炎性关节炎患者(平均50.4±15.7岁,10例男性)。
  • 所有患者在首次IFN-α(4小时)或抗TNF(24小时)注射前后完成fMRI情绪面孔任务和血样采集,并随访精神科评估3个月。

主要发现

  • IFN-α在4周时显著增加HAM-D抑郁症状(p < 0.001),但首次剂量后4小时未显著增加(p > 0.1)。
  • 抗TNF在24小时(P = 0.015)和12周(p = 0.018)均显著改善HADS抑郁症状。
  • IFN-α急性增强右侧杏仁核对悲伤(相比中性)面孔的反应(p = 0.032),抗TNF则降低右侧杏仁核反应性(跨情绪效价)(p = 0.033)。
  • 杏仁核反应性变化预测IFN-α诱导的4周后HAM-D增加(R2 = 0.17,p = 0.022)和抗TNF相关的24小时HADS下降(R2 = 0.23,p = 0.01)。

临床怎么用

  • 临床中可关注接受IFN-α或抗TNF治疗患者的抑郁症状变化,尤其早期杏仁核反应性改变可能提示后续抑郁转归。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A third of patients receiving Interferon-α (IFN-α) treatment for Hepatitis-C develop major depressive disorder (MDD). Conversely, anti-Tumor Necrosis Factor (TNF) therapies improve depression providing key empirical support for the "inflammatory theory" of depression. Heightened amygdala reactivity (particularly to negatively valanced stimuli) is a consistent finding within MDD; can predict treatment efficacy and reverses following successful treatment. However, whether IFN-α and anti-TNF enhance/attenuate depressive symptoms through modulation of amygdala emotional reactivity is unknown. Utilizing a prospective study design, we recruited 30 patients (mean 48.0 ± 10.5 years, 21 male) initiating IFN-α treatment for Hepatitis-C and 30 (mean 50.4 ± 15.7 years, 10 male) anti-TNF therapy for inflammatory arthritis. All completed an emotional face-processing task during fMRI and blood sampling before and after their first IFN-α (4-h) or anti-TNF (24-h) injection and follow-up psychiatric assessments for 3 months of treatment. IFN-α significantly increased depression symptoms (Hamilton Depression Rating Scale HAM-D) at 4 weeks (p < 0.001) but not 4-h after first dose (p > 0.1). Conversely, anti-TNF significantly improved depressive symptoms (Hospital Anxiety and Depression Rating Scale HADS) at both 24-h (P = 0.015) and 12 weeks (p = 0.018). In support of our a-priori hypothesis, both IFN-α and anti-TNF significantly modulated amygdala reactivity with IFN-α acutely enhancing right amygdala responses to sad (compared with neutral) faces (p = 0.032) and anti-TNF conversely decreasing right amygdala reactivity (across emotional valence) (p = 0.033). Furthermore, these changes predicted IFN-induced increases in HAM-D 4 weeks later (R2 = 0.17, p = 0.022) and anti-TNF-associated decreases in HADS at 24-h (R2 = 0.23, p = 0.01) suggesting that actions of systemic inflammation on amygdala emotional reactivity play a mechanistic role in inflammation-associated depressive symptoms.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Davies KA, Cooper E, Voon V, et al. Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms. Mol Psychiatry. 2020. PMID: 32457424. doi:10.1038/s41380-020-0790-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。